Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - Results from a prospective, observational study in Germany.

Jackisch C, Welslau M, Schoenegg W, Selbach J, Harich HD, Schröder J, Schmidt M, Göhler T, Eustermann H, Ringel R, Hinke A.

Breast. 2014 Jul 8. pii: S0960-9776(14)00113-1. doi: 10.1016/j.breast.2014.06.003. [Epub ahead of print]

PMID:
25012046
[PubMed - as supplied by publisher]
2.

Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.

Straka C, Salwender H, Schnabel B, Sandherr M, Wandt H, Hübel K, Scheid C, Metzner B, Hentrich M, Franke D, Weidenegger G, Freund M, Sezer O, Einsele H, Hinke A, Emmerich B.

Leuk Lymphoma. 2014 May 27:1-9. [Epub ahead of print]

PMID:
24794810
[PubMed - as supplied by publisher]
3.

Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96-02/AUO AP 09/95 Trial.

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K.

Eur Urol. 2014 Mar 21. pii: S0302-2838(14)00247-4. doi: 10.1016/j.eururo.2014.03.011. [Epub ahead of print]

PMID:
24680359
[PubMed - as supplied by publisher]
4.

Response.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2014 Mar;106(3):djt452. doi: 10.1093/jnci/djt452. Epub 2014 Feb 28. No abstract available.

PMID:
24586093
[PubMed - indexed for MEDLINE]
5.

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.

Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G, Theurich S, Christopeit M, Mohren M, Reichle A, Metzner B, Ganser A, Stadler M, Uharek L, Balleisen L, Hinke A, Hinke R, Niederwieser D.

Bone Marrow Transplant. 2014 Mar;49(3):410-5. doi: 10.1038/bmt.2013.199. Epub 2013 Dec 23.

PMID:
24362366
[PubMed - in process]
6.

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H.

JAMA. 2013 Oct 9;310(14):1473-81. doi: 10.1001/jama.2013.279201.

PMID:
24104372
[PubMed - indexed for MEDLINE]
7.

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.

Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT.

Br J Cancer. 2013 Sep 17;109(6):1408-13. doi: 10.1038/bjc.2013.409. Epub 2013 Aug 20.

PMID:
23963139
[PubMed - indexed for MEDLINE]
8.

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2013 Jul 17;105(14):1018-26. doi: 10.1093/jnci/djt145. Epub 2013 Jul 16.

PMID:
23860204
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis.

Bottke D, Golz R, Störkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T.

Eur Urol. 2013 Aug;64(2):193-8. doi: 10.1016/j.eururo.2013.03.029. Epub 2013 Mar 17.

PMID:
23522911
[PubMed - indexed for MEDLINE]
10.

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.

Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U.

Ann Oncol. 2013 Jun;24(6):1580-7. doi: 10.1093/annonc/mdt028. Epub 2013 Mar 4.

PMID:
23463625
[PubMed - indexed for MEDLINE]
Free Article
11.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL).

Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184.

PMID:
23433739
[PubMed - indexed for MEDLINE]
12.

Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.

Niederle N, Megdenberg D, Balleisen L, Heit W, Knauf W, Weiß J, Freier W, Hinke A, Ibach S, Eimermacher H.

Ann Hematol. 2013 May;92(5):653-60. doi: 10.1007/s00277-012-1660-6. Epub 2013 Jan 23.

PMID:
23340738
[PubMed - indexed for MEDLINE]
13.

Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer.

Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Löhrs B, Toth B, Von Koch F, Kahlert S, Bauerfeind I, Konecny GE, Loibl S, VON Minckwitz G, Untch M.

Anticancer Res. 2012 Aug;32(8):3539-45.

PMID:
22843943
[PubMed - indexed for MEDLINE]
14.

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.

John M, Hinke A, Stauch M, Wolf H, Mohr B, Hindenburg HJ, Papke J, Schlosser J; FAKT Study Group.

BMC Cancer. 2012 May 4;12:165.

PMID:
22559145
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

IMWG consensus on maintenance therapy in multiple myeloma.

Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M; International Myeloma Working Group.

Blood. 2012 Mar 29;119(13):3003-15. doi: 10.1182/blood-2011-11-374249. Epub 2012 Jan 23. Review.

PMID:
22271445
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Kahl C, Sayer HG, Hinke A, Freund M, Casper J.

J Cancer Res Clin Oncol. 2012 Mar;138(3):513-7. doi: 10.1007/s00432-011-1116-8. Epub 2011 Dec 25.

PMID:
22198675
[PubMed - indexed for MEDLINE]
17.

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V.

BMC Cancer. 2011 Aug 23;11:367. doi: 10.1186/1471-2407-11-367.

PMID:
21861888
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

J Clin Oncol. 2011 Oct 1;29(28):3791-7. doi: 10.1200/JCO.2010.30.4899. Epub 2011 Aug 22.

PMID:
21860000
[PubMed - indexed for MEDLINE]
19.

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P.

Eur J Cancer. 2011 Oct;47(15):2306-14. doi: 10.1016/j.ejca.2011.06.002.

PMID:
21742485
[PubMed - indexed for MEDLINE]
20.

Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy].

Jensen AD, Nikoghosyan A, Hinke A, Debus J, Münter MW.

BMC Cancer. 2011 Feb 15;11:70. doi: 10.1186/1471-2407-11-70.

PMID:
21320355
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk